AstraZeneca PLC (OTCMKTS:AZNCF – Get Free Report) was the target of a significant decrease in short interest in June. As of June 15th, there was short interest totalling 12,200 shares, a decrease of 41.9% from the May 31st total of 21,000 shares. Based on an average daily volume of 3,600 shares, the days-to-cover ratio is currently 3.4 days.
Institutional Trading of AstraZeneca
A hedge fund recently bought a new stake in AstraZeneca stock. Kennedy Capital Management LLC bought a new stake in AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 37,554 shares of the company’s stock, valued at approximately $5,068,000. Hedge funds and other institutional investors own 40.87% of the company’s stock.
AstraZeneca Price Performance
Shares of AZNCF opened at $158.64 on Friday. AstraZeneca has a 1 year low of $118.16 and a 1 year high of $162.00. The company’s 50-day simple moving average is $153.62 and its 200-day simple moving average is $139.65.
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Read More
- Five stocks we like better than AstraZeneca
- Earnings Per Share Calculator: How to Calculate EPS
- Albemarle Stock: Strong Fundamentals vs. Lithium Volatility
- Conference Calls and Individual Investors
- MongoDB Stock: Analysts Recommend Buying the Dip
- The How And Why of Investing in Oil Stocks
- UniFirst Stock: Value-Building Sends a Signal to the Market
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.